The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia
- Registration Number
- NCT04374591
- Lead Sponsor
- Mansoura University
- Brief Summary
To report the possible role of S.B 8.4% in the treatment of COVID-19pneumonia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- Age >18 years.
- Fever ≥ 38º C with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea.
- Chest CT with signs suggestive of COVID-19.
- Mild and moderate cases of COVID-19 pneumonia with respiratory and hemodynamic stability. - High C reactive protein (CRP).- With or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have RT-PCR positive test for COVID-19
- With or without abnormalities in the total or differential white cell count.
- Welling to sign a fully informed consent.
Exclusion Criteria
- Severe and critical illness with respiratory failure and/ or hemodynamic instability.
- CT with pleural effusion with or without lung cavitation.
- Other organ failure.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sodium Bicarbonate Sodium Bicarbonate Inhalation of Sodium Bicarbonate 8.4% via nebulizer Control Sodium Bicarbonate placebo
- Primary Outcome Measures
Name Time Method Time to clinical recovery 7 days defined as return of body temperature and relief of cough for more than 72 hours measured in days
- Secondary Outcome Measures
Name Time Method Pulmonary recovery status 7 days assessed by Chest CT defined as exacerbated, unchanged, moderately improved (with less than 50% pneumonia resolved) and significantly improved (with more than 50% pneumonia resolved).
Trial Locations
- Locations (1)
Gomhoria Street
🇪🇬Mansoura, Outside U.S./Canada, Egypt